Recent oncology conferences have unveiled a wave of discoveries that could reshape cancer treatment for patients worldwide. At the 34th Asian Pacific Liver Meeting, Prof. Liu Jia explained how the immune checkpoint PD‑1 acts like a double‑edged sword in hepatitis B infection—boosting virus‑specific CD8+ T‑cell growth during the acute phase while behaving differently in chronic settings, opening fresh research avenues. In a Lancet‑published trial (HARMONi‑6), the bispecific antibody ivuximab paired with chemotherapy dramatically extended progression‑free survival for people with advanced squamous non‑small cell lung cancer, outperforming the standard tislelizumab combo and showing manageable side effects. Meanwhile, a Cell Metabolism team led by Prof. Zhang Zhiren discovered that PD‑1 on macrophages isn’t just an immune brake; it safeguards metabolic balance during immunotherapy, hinting at new ways to curb treatment‑related toxicity. The TREND neoadjuvant study, presented by Prof. Xu Yingying and Prof. Zhu Bo, reported promising results for triple‑negative breast cancer patients receiving pre‑surgery immunotherapy. A large‑scale single‑cell atlas further revealed five distinct immune‑microenvironment subtypes in NSCLC patients on anti‑PD‑1 therapy, each linked to unique response patterns. A groundbreaking Nature paper now re‑labels PD‑1 as a “guardian” of high‑quality T cells, challenging long‑held dogma. Finally, JAMA Oncology highlighted that combining messenger RNA vaccines with PD‑1 blockade drove an 80% response rate in high‑risk, surgically challenging breast cancers, offering a hopeful new therapeutic route.
Read more